Phase I trial of the investigational aurora A kinase (AAK) inhibitor MLN8237 (alisertib) in combination with docetaxel (DTX) in patients (pts) with advanced solid tumors, including castration-resistant prostate cancer (CRPC).
John Sarantopoulos
No relevant relationships to disclose
Noah M. Hahn
Consultant or Advisory Role - Celgene; Sanofi
Honoraria - Janssen Biotech; Sanofi
Research Funding - Bristol-Myers Squibb; Celgene; Dendreon; Exelixis; Merck; Millennium; Novartis; Sanofi
Celestia S. Higano
Honoraria - AbbVie; Amgen; Bayer; BHR Pharma; Dendreon; Endo/Orion; Ferring; Fresenius ; Genentech; Janssen; Medivation; Novartis; Pfizer
Research Funding - Algeta; Amgen; Aragon Pharmaceuticals; AstraZeneca; Bayer; Dendreon; Exelixis; Genentech; ImClone Systems; Medarex; Medivation; Millennium; Nerviano; Oncogenex; Sanofi ; Teva
E. Jane Leonard
Employment or Leadership Position - Takeda
Stock Ownership - Takeda
Bin Zhang
Employment or Leadership Position - Takeda
Stock Ownership - Takeda
Xiaofei Zhou
Employment or Leadership Position - Takeda
Claudio Dansky Ullmann
Employment or Leadership Position - Takeda
Stock Ownership - Takeda
Julie Nicole Graff
No relevant relationships to disclose